4 patents currently held
7 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
The next term ends in May 2032. from the record
Of the 7 now held by other companies, 3 name Pacira Pharmaceuticals Inc. as their current owner, and 4 more name another party. Each row says which.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
0
Ending by 2030
May 2032
Next term end
4
Patent families
When these terms end
Held patents by the year their term ends
notable patents
all others
Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Only 1 of the currently held patents qualifies as notable.
Formerly held, still cited
Notable
Ends Dec 2035 · High confidence
Granted 2021. Computed term ends 2035.
now held by Pacira Pharmaceuticals, Inc.
Also notable
Ends Feb 2033 · High confidence
Granted 2016 and renewed at every maintenance window due so far. Protection runs to 2033.
now held by Philanthropos Therapeutics LLC
Also notable
Ends Oct 2032 · Medium confidence
Granted 2018 and renewed at every maintenance window due so far. Protection runs to 2032.
now held by Tekv Therapeutics, LLC
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Oct 16, 2027The maintenance fee for Proteasome Activity Enhancing Compounds (US 11,958,873) comes due Oct 16, 2027. Unpaid by Apr 17, 2028, it lapses early.
Recent changes
- 1 of the patents on this record was granted since Aug 17, 2026
What they patent
Grouped by real patent family, largest first, labeled by the earliest filing in each. No technology classification is inferred from titles.
| Anti-Vista Antibodies and Uses Thereof | 1 in force | to Jun 2043 |
| Proteasome Activity Enhancing Compounds (2022) | 1 in force | to Sep 2039 |
| Proteasome Activity Enhancing Compounds (2021) | 1 in force | to Jan 2035 |
| Proteostasis Regulators | 1 in force | to May 2032 |
Patents held now
Soonest term end first.
Showing 1 to 4 of 4
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 12,180,189 | Proteostasis Regulators In force · Medium confidence | In force | Medium confidence | |
| US 11,958,873 | Proteasome Activity Enhancing Compounds In force · Medium confidence | In force | Medium confidence | |
| US 12,319,698 | Proteasome Activity Enhancing Compounds held by Yumanity Therapeutics, Inc. In force · Medium confidence | In force | Medium confidence | |
| US 12,760,104 | Anti-Vista Antibodies and Uses Thereof In force · High confidence | In force | High confidence |
Also on record, not counted in the 4: 7 patents in force now held by others · 6 patents ended · 9 applications pending · 13 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
1 terminal disclaimer is on file with no resolved reference. No cap is applied and none is guessed
4 computed term dates come from a chain with an unresolved parent. A continuity parent has not yet been fetched from USPTO's records. The term is dated from this application's own claim; no earlier date is assumed until the parent is resolved.